Euroopa Liit - eesti - EMA (European Medicines Agency)

novartis europharm limited  - indacaterol, mometasone furoate - astma - ravimid hingamisteede obstruktiivsete haiguste, - bemrist breezhaler is indicated as a maintenance   treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists.

Euroopa Liit - eesti - EMA (European Medicines Agency)

novartis europharm limited  - indacaterol acetate, mometasone furoate - astma - ravimid hingamisteede obstruktiivsete haiguste, - atectura breezhaler is indicated as a maintenance treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists.

Eesti - eesti - Ravimiamet

zentiva k.s. - salmeterool+flutikasoon - annustatud inhalatsioonipulber - 50mcg+500mcg 1annus 60annus 1tk; 50mcg+500mcg 1annus 60annus 10tk; 50mcg+500mcg 1annus 60annus 2tk

Eesti - eesti - Ravimiamet

zentiva k.s. - salmeterool+flutikasoon - annustatud inhalatsioonipulber - 50mcg+100mcg 1annus 60annus 1tk; 50mcg+100mcg 1annus 60annus 2tk; 50mcg+100mcg 1annus 60annus 10tk; 50mcg+100mcg 1annus 60annus 3tk

Eesti - eesti - Ravimiamet

zentiva k.s. - salmeterool+flutikasoon - annustatud inhalatsioonipulber - 50mcg+250mcg 1annus 60annus 3tk; 50mcg+250mcg 1annus 60annus 1tk; 50mcg+250mcg 1annus 60annus 10tk

Eesti - eesti - Ravimiamet

sandoz pharmaceuticals d.d. - formoterool+budesoniid - annustatud inhalatsioonipulber - 9mcg+320mcg 1mõõtannus 60mõõtannus 3tk; 9mcg+320mcg 1mõõtannus 60mõõtannus 6tk; 9mcg+320mcg 1mõõtannus 60mõõtannus 2tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

teva b.v. - salmeterol xinafoate, fluticasone propionaat - astma - ravimid hingamisteede obstruktiivsete haiguste, - bropair spiromax is indicated in the regular treatment of asthma in adults and adolescents aged 12 years and older not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled short-acting β₂ agonists.

Euroopa Liit - eesti - EMA (European Medicines Agency)

teva b.v. - fluticasone propionate, salmeterol xinafoate - astma - ravimid hingamisteede obstruktiivsete haiguste, - seffalair spiromax is indicated in the regular treatment of asthma in adults and adolescents aged 12 years and older not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled short-acting β₂ agonists.

Eesti - eesti - Ravimiamet

viatris limited - formoterool+beklometasoon - inhalatsiooniaerosool, lahus - 6mcg+100mcg 1annus 120annus 2tk; 6mcg+100mcg 1annus 120annus 1tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

glaxosmithkline (ireland) limited - umeclidinium bromiid, vilanterol trifenatate - kopsuhaigus, krooniline obstruktiivne - ravimid hingamisteede obstruktiivsete haiguste, - anoro ellipta on näidustatud hooldus bronchodilator ravi, et leevendada sümptomeid täiskasvanud patsientidel, kellel on krooniline obstruktiivne kopsuhaigus (copd).